Cargando…
Biomarkers of Treatment Toxicity in Combined-Modality Cancer Therapies with Radiation and Systemic Drugs: Study Design, Multiplex Methods, Molecular Networks
Organ toxicity in cancer therapy is likely caused by an underlying disposition for given pathophysiological mechanisms in the individual patient. Mechanistic data on treatment toxicity at the patient level are scarce; hence, probabilistic and translational linkages among different layers of data inf...
Autores principales: | Ree, Anne Hansen, Meltzer, Sebastian, Flatmark, Kjersti, Dueland, Svein, Kalanxhi, Erta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4284741/ https://www.ncbi.nlm.nih.gov/pubmed/25501337 http://dx.doi.org/10.3390/ijms151222835 |
Ejemplares similares
-
Circulating proteins in response to combined-modality therapy in rectal cancer identified by antibody array screening
por: Kalanxhi, Erta, et al.
Publicado: (2016) -
Biomarkers of Histone Deacetylase Inhibitor Activity in a Phase 1 Combined-Modality Study with Radiotherapy
por: Ree, Anne Hansen, et al.
Publicado: (2014) -
Systemic release of osteoprotegerin during oxaliplatin-containing induction chemotherapy and favorable systemic outcome of sequential radiotherapy in rectal cancer
por: Meltzer, Sebastian, et al.
Publicado: (2016) -
Circulating Exosomal miR-141-3p and miR-375 in Metastatic Progression of Rectal Cancer
por: Meltzer, Sebastian, et al.
Publicado: (2019) -
Corrigendum to “Circulating Exosomal miR-141-3p and miR-375 in Metastatic Progression of Rectal Cancer” [Transl Oncol 12 (8) (2019) 1038–1044]
por: Meltzer, Sebastian, et al.
Publicado: (2019)